Amgen’s European EPO Sales Unaffected By Biosimilars – For Now
This article was originally published in The Pink Sheet Daily
European biosimilars competing against first-generation erythropoietins, Amgen notes during Q3 earnings call.
You may also be interested in...
Proposed EPO labeling that sets target hemoglobin levels in 10-12 g/dL range is consistent with European prescribing practices, analysts note.
Sandoz Will Launch Biosimilar Epoetin Alfa In Europe At Up To 30 Percent Discount To Branded Products
EU approval further demonstrates need for U.S. follow-on pathway, Sandoz VP-Global Head of Biopharma Development Ajaz Hussain tells “The Pink Sheet” DAILY.
Sandoz is set to launch its biosimilar, Binocrit, in 2007 following commission approval, the firm tells “The Pink Sheet” DAILY.